Weil Company’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Weil Company’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-400	Closed	-$1K	–	364
2019 Q3	$1K	Buy	+400	New	+$932	﹤0.01%	382

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Weil Company's SRNE Position: Q4 2019 in Review

Weil Company sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2019, closing a stake of 400 shares — an estimated $1K sold.

Weil Company first reported a position in SRNE in Q3 2019 and held it in 1 quarter. The position peaked at $1K in Q3 2019. 88 funds tracked by Wall St. Rank hold SRNE as of Q4 2019.

Weil Company reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
Weil Company sold 400 Sorrento Therapeutics, Inc. shares in Q4 2019, an estimated $1K.
Weil Company first reported a position in Sorrento Therapeutics, Inc. in Q3 2019 and held it in 1 quarter.
Weil Company's Sorrento Therapeutics, Inc. position peaked at $1K in Q3 2019.
88 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2019.

Based on Weil Company's 13F filing for Q4 2019, filed 13 Feb 2020.